Cargando…

Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study

Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of...

Descripción completa

Detalles Bibliográficos
Autores principales: Moniuszko-Malinowska, Anna, Czupryna, Piotr, Zarębska-Michaluk, Dorota, Tomasiewicz, Krzysztof, Pancewicz, Sławomir, Rorat, Marta, Dworzańska, Anna, Sikorska, Katarzyna, Bolewska, Beata, Lorenc, Beata, Chciałowski, Andrzej, Kozielewicz, Dorota, Oczko-Grzesik, Barbara, Szymanek-Pasternak, Anna, Szetela, Bartosz, Figlerowicz, Magdalena, Rogalska, Magdalena, Zaleska, Izabela, Flisiak, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795721/
https://www.ncbi.nlm.nih.gov/pubmed/33374333
http://dx.doi.org/10.3390/jcm10010028
_version_ 1783634511612870656
author Moniuszko-Malinowska, Anna
Czupryna, Piotr
Zarębska-Michaluk, Dorota
Tomasiewicz, Krzysztof
Pancewicz, Sławomir
Rorat, Marta
Dworzańska, Anna
Sikorska, Katarzyna
Bolewska, Beata
Lorenc, Beata
Chciałowski, Andrzej
Kozielewicz, Dorota
Oczko-Grzesik, Barbara
Szymanek-Pasternak, Anna
Szetela, Bartosz
Figlerowicz, Magdalena
Rogalska, Magdalena
Zaleska, Izabela
Flisiak, Robert
author_facet Moniuszko-Malinowska, Anna
Czupryna, Piotr
Zarębska-Michaluk, Dorota
Tomasiewicz, Krzysztof
Pancewicz, Sławomir
Rorat, Marta
Dworzańska, Anna
Sikorska, Katarzyna
Bolewska, Beata
Lorenc, Beata
Chciałowski, Andrzej
Kozielewicz, Dorota
Oczko-Grzesik, Barbara
Szymanek-Pasternak, Anna
Szetela, Bartosz
Figlerowicz, Magdalena
Rogalska, Magdalena
Zaleska, Izabela
Flisiak, Robert
author_sort Moniuszko-Malinowska, Anna
collection PubMed
description Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible.
format Online
Article
Text
id pubmed-7795721
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77957212021-01-10 Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study Moniuszko-Malinowska, Anna Czupryna, Piotr Zarębska-Michaluk, Dorota Tomasiewicz, Krzysztof Pancewicz, Sławomir Rorat, Marta Dworzańska, Anna Sikorska, Katarzyna Bolewska, Beata Lorenc, Beata Chciałowski, Andrzej Kozielewicz, Dorota Oczko-Grzesik, Barbara Szymanek-Pasternak, Anna Szetela, Bartosz Figlerowicz, Magdalena Rogalska, Magdalena Zaleska, Izabela Flisiak, Robert J Clin Med Article Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible. MDPI 2020-12-24 /pmc/articles/PMC7795721/ /pubmed/33374333 http://dx.doi.org/10.3390/jcm10010028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moniuszko-Malinowska, Anna
Czupryna, Piotr
Zarębska-Michaluk, Dorota
Tomasiewicz, Krzysztof
Pancewicz, Sławomir
Rorat, Marta
Dworzańska, Anna
Sikorska, Katarzyna
Bolewska, Beata
Lorenc, Beata
Chciałowski, Andrzej
Kozielewicz, Dorota
Oczko-Grzesik, Barbara
Szymanek-Pasternak, Anna
Szetela, Bartosz
Figlerowicz, Magdalena
Rogalska, Magdalena
Zaleska, Izabela
Flisiak, Robert
Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title_full Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title_fullStr Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title_full_unstemmed Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title_short Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
title_sort convalescent plasma transfusion for the treatment of covid-19—experience from poland: a multicenter study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795721/
https://www.ncbi.nlm.nih.gov/pubmed/33374333
http://dx.doi.org/10.3390/jcm10010028
work_keys_str_mv AT moniuszkomalinowskaanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT czuprynapiotr convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT zarebskamichalukdorota convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT tomasiewiczkrzysztof convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT pancewiczsławomir convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT roratmarta convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT dworzanskaanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT sikorskakatarzyna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT bolewskabeata convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT lorencbeata convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT chciałowskiandrzej convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT kozielewiczdorota convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT oczkogrzesikbarbara convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT szymanekpasternakanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT szetelabartosz convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT figlerowiczmagdalena convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT rogalskamagdalena convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT zaleskaizabela convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy
AT flisiakrobert convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy